Soliton Inc., a Houston-based medical device startup has raised $9 million for further development of technology created at the University of Texas M.D. Anderson Cancer Center, according to an SEC filing.
Soliton’s technology is designed to use electro-hydraulic generated shockwaves to help with various medical and cosmetic treatments, which could include procedures to reduce the appearance of tattoos and treat certain medical conditions, according to the filed patent.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
According to Houston Business Journal, Soliton has raised around $12 million in total and has currently declined to comment on details concerning the progress of the company and technology. The most recent $9 million was raised by one undisclosed investor. The company will reportedly be operating under the radar for the next 18 months and did not respond to a phone call.
Walter Klemp, Soliton’s CEO, has previously worked with M.D. Anderson spinoff companies. He was previously the CEO of Tyrell Inc., which created the acne treatment device Zeno, and according to his LinkedIn page is also the CEO of pharmaceutical company Moleculin and founding partner of NaukaMed.
Chris Capelli, Soliton’s cheif science officer was also previously the vice president of technology based ventures at M.D. Anderson.
Photo: Flickr user zzzack
